Clinical utility of milnacipran in comparison with other antidepressants

International Clinical Psychopharmacology

Volumn 17, Issue SUPPL. 1, 2002, Pages

  Bisserbe, Jean Claude ^a  

^a Centre d'Immunologie Pierre Fabre   (France)

Author keywords

Depression; Efficacy; Milnacipran; Relapse; Suicide; Tolerance

Indexed keywords

FLUOXETINE; FLUVOXAMINE; MILNACIPRAN; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; ANTIDEPRESSANT AGENT; CYCLOPROPANE DERIVATIVE;

ANXIETY NEUROSIS; AUTONOMIC DYSFUNCTION; CONFERENCE PAPER; CONSTIPATION; DEPRESSION; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DYSURIA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HUMAN; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; RATING SCALE; RECURRENT DISEASE; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; SUICIDE; SWEATING; TREMOR; VERTIGO; XEROSTOMIA; CLINICAL TRIAL; COMPARATIVE STUDY; PSYCHOLOGICAL ASPECT; REVIEW;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CLINICAL TRIALS; CYCLOPROPANES; DEPRESSIVE DISORDER;

EID: 0036298405     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200206001-00006     Document Type: Conference Paper

References (55)

1. The efficacy of selective serotonin re-uptake inhibitors in depression: A metaanalysis of studies against tricyclic antidepressants
2. Natural history and epidemiology of depression
3. Comorbidity of recurrent brief depression
4. Controlled comparison of milnacipran (F2207) 200 mg and amitriptyline in endogenous depressive inpatients
5. Controlled comparison of milnacipran (F2207) 200 mg and amitriptyline in endogenous depression
6. Interest of a loading dose of milnacipran in endogenous depressive patients
7. Controlled comparison of milnacipran and fluoxetine in endogenous depressive patients
8. Fluoxetine and suicide: A meta-analysis of controlled trials of treatment for depression
9. Antidepressant response to tricyclics and urinary MHPG in unipolar patients. Clinical response to imipramine or amitriptyline
10. Therapeutic contribution of milnacipran and of clomipramine during a 3-month treatment: Results of a comparative study
11. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia
12. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: A comparison with fluvoxamine
13. The toxicity of drugs used for suicide
14. Clinical evaluation of milnacipran, a new antidepressant for depression and depressive state. Phase III clinical trial with mianserin hydrochloride as a control drug
15. The morbidity and mortality of clinical depression
16. The neuropharmacology of serotonin and noradrenaline in depression
17. Predictors of an acute antidepressant response to fluoxetine and sertraline
18. Predictors of the antidepressant response
19. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients
20. Suicide and primary affective disorders
21. Development of a rating scale for primary depressive illness
22. Antidepressants and suicide
23. Dimensional assessment of onset of action of antidepressants: A comparative study of moclobemide vs. clomipramine in depressed patients with blunted affect and psychomotor retardation
24. Predictors of drug response in depression
25. The place of milnacipran in the treatment of depression
26. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: A summary of clinical trial results
27. Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects
28. Long-term treatment of depression
29. Neuropharmacology of antidepressants that modify central noradrenergic and serotonergic function: A short review
30. Milnacipran and selective serotonin reuptake inhibitors in major depression
31. Pattern of recurrence of illness after recovery from an episode of major depression: A prospective study
32. Clinical evaluation of milnacipran hydrochloride (TN-912) on depression and depressive states. Phase III clinical trial with imipramine hydrochloride as a control drug
33. Suicide prevention: The role of antidepressants
34. A new depression scale designed to be sensitive to change
35. Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo
36. Efficacy and tolerability of milnacipran: An overview
37. Effects of milnacipran and pindolol on extracellular noradrenaline and serotonin levels in guinea pig hypothalamus
38. Biochemical profile of midalcipran, 1-phenyl-1-diethylaminocarbonyl-2-aminoethylcyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug
39. A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression
40. Evolution of remission as the new standard in the treatment of depression
41. Are there differential effects of fluoxetine in retarded/blunted affect versus agitated/ anxious depressives? A clinical study
42. The pharmacological treatment of depression
43. Long-term treatment of mood disorders. The fourth generation in progress
44. Milnacipran efficacy in the prevention of recurrent depression: A 12-month placebo-controlled study
45. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression
46. Psychomotor retardation as a predictive factor favouring a positive clinical response to milnacipran
47. Recognition and treatment of depression in the elderly
48. Milnacipran. A review of its use in depression
49. Future imperfect: The long-term outcome of depression
50. Emergence of intense suicidal preoccupating during fluoxetine treatment
51. Double blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode
52. Evaluation of suicidality during pharmacologic treatment of mood and nonmood disorders
53. Beyond serotonin. A multi-aminergic perspective on abnormal behavior
54. Pooling two controlled comparisons of milnacipran (F2207) and amitriptyline in endogenous inpatients. A new approach in dose ranging studies
55. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: A literature review